柳药集团2月25日获融资买入1881.74万元，融资余额4.30亿元

Core Viewpoint - Liuyao Group has experienced a decline in stock performance and financial metrics, indicating potential challenges in its operational efficiency and market position [1][2]. Group 1: Stock Performance - On February 25, Liuyao Group's stock fell by 0.06%, with a trading volume of 114 million yuan [1]. - The financing buy-in amount for Liuyao Group on the same day was 18.82 million yuan, while the financing repayment was 29.49 million yuan, resulting in a net financing buy of -10.67 million yuan [1]. - As of February 25, the total financing and securities lending balance for Liuyao Group was 430 million yuan, accounting for 6.01% of its market capitalization, which is below the 10% percentile level over the past year [1]. Group 2: Financial Performance - For the period from January to September 2025, Liuyao Group reported an operating income of 15.758 billion yuan, a year-on-year decrease of 1.47% [2]. - The net profit attributable to shareholders for the same period was 646 million yuan, reflecting a year-on-year decline of 9.81% [2]. Group 3: Shareholder Information - As of September 30, 2025, Liuyao Group had 30,400 shareholders, a decrease of 7.62% compared to the previous period [2]. - The average number of circulating shares per shareholder increased by 8.25% to 13,050 shares [2]. - Cumulatively, Liuyao Group has distributed 1.789 billion yuan in dividends since its A-share listing, with 720 million yuan distributed over the past three years [3].